ETRA — IPO pricing analysis (2026-09-19)

Electra's IPO is a bet that a 12-patient mHLH signal travels to the majority of secondary HLH that malignancy does not cause

Electra Therapeutics priced $350,000,010 at $15.00 per share — the midpoint of its $14.00 to $16.00 marketed range — on 23,333,334 shares, slightly more than the 21.7 million originally marketed. Allocators took volume at the midpoint rather than bidding the price up, which in a biotech window BioSpace described as a surge with more listings already than all of 2025 (BioSpace, September 18, 2026) is a legible signal: the book had breadth but not price-insensitive conviction.

The resulting market capitalization is approximately $941,004,825. Pro forma cash after the offering stands at $417,575,000 — roughly 44% of that market cap. Strip out the cash and the clinical franchise — a pan-SIRP antibody with FDA Breakthrough Therapy designation and EMA PRIME designation, a running registrational trial, and a second asset in Phase 1 — is implicitly valued at approximately $523,429,825. Against $301,400,000 of cumulative private capital raised since inception, that is a restrained mark. The market is not pricing this as if the Phase 1b numbers replicate perfectly across the full sHLH population — and that restraint is the strongest argument available to the bull case.

Quick Facts
Offer price	$15.00/share
Shares offered (excl. greenshoe)	23,333,334
Greenshoe	3,500,000 shares (30-day option)
Gross proceeds (excl. greenshoe)	$350,000,010
Net proceeds after discounts and expenses (excl. greenshoe)	$319,900,000
Post-IPO shares outstanding (excl. greenshoe)	62,766,955
Pro forma cash (post-IPO)	$417,575,000
Funded into	2029
Employees	46

---

The evidence base and the ask are not the same population

The entire investment case rests on ipsoprubart's Phase 1b data. In 12 frontline patients with malignancy-associated HLH (mHLH), the drug produced 100% 8-week overall survival and 100% overall response rate — 10 partial responses and 2 modified complete responses. All 11 patients evaluable for hospital discharge were discharged. The historical 2-month overall survival benchmark with existing treatments in mHLH is approximately 50%. On its face, the signal is extraordinary.

The problem is where the registrational trial points. mHLH represents approximately 45% of all secondary HLH (sHLH). SURPASS, Electra's pivotal study, enrolls newly diagnosed, treatment-naïve sHLH broadly — which means the majority of sHLH triggered by infection, autoimmune disease, or other non-malignant causes is inside the trial population. Both the FDA's Breakthrough Therapy designation and the EMA's PRIME designation were granted for sHLH broadly. So the designations, the trial design, and the commercial model all reach into a population where the human proof-of-concept is thin.

The mechanism is where this specific risk lives. Ipsoprubart is a pan-SIRP antibody with an enhanced Fc domain that kills SIRP-expressing cells through antibody-dependent cytotoxicity and phagocytosis. In mHLH, the cells driving hyperinflammation and the cells constituting the underlying malignancy are frequently the same lineage — which makes the drug simultaneously oncologic and anti-inflammatory in this subset. That reading is what makes the tumor data coherent: across 8 evaluable sHLH patients with T or B cell lymphomas, ipsoprubart produced a 100% objective tumor response rate, with 7 of 8 achieving complete responses and an 88% complete response rate in T/NK malignancy patients across the Phase 1b and Expanded Access Program.

In infection-triggered sHLH, the calculus shifts. The activated myeloid cells and T cells ipsoprubart depletes are simultaneously the pathology and the pathogen clearance apparatus. Electra's steelman — that the drug preserves host defense by sparing naïve and regulatory populations — may well hold. It is a nonclinical argument being asked to carry the non-malignancy portion of a registrational population, and the prospectus does not present frontline human efficacy data in non-malignancy sHLH at anything approaching the depth of the mHLH set.

---

The external-control design is the second load-bearing assumption

SURPASS reads against COMPASS, a natural history study Electra is itself running to supply the comparator arm, with both targeting enrollment completion in the second half of 2027. An external control drawn from a company-run natural history study is a defensible regulatory path in a rare, rapidly fatal disease with no broadly approved therapy — Breakthrough Therapy designation signals the FDA was willing to engage on that design. The exposure is confounding by trigger mix.

sHLH outcomes vary significantly by underlying cause; the filing characterizes mHLH as the sHLH subset with the poorest prognosis. If SURPASS enrolls a materially different trigger distribution than COMPASS — more mHLH in the treatment arm, more infection-associated cases in the control arm, or vice versa — the survival delta becomes a negotiation over case-mix adjustment rather than a clean data read. Electra's own risk language concedes this directly: regulators may not agree that a trial Electra believes is successful provides adequate evidence of safety or efficacy. In a single-arm-plus-external-control design, that sentence carries weight.

---

The burn curve

Period	R&D	G&A	Total opex	Net loss
H1 2025	$18,792,000	$5,921,000	$25,369,000	$(25,361,000)
H1 2026	$41,637,000	$8,593,000	$50,230,000	$(48,912,000)
FY 2024	$19,267,000	$5,241,000	$26,317,000	$(24,786,000)
FY 2025	$50,387,000	$10,390,000	$61,889,000	$(61,975,000)

Total operating expense nearly doubled year over year in the first half — $50,230,000 versus $25,369,000, up approximately 98% — with R&D accounting for approximately 83% of the H1 2026 total. Accumulated deficit stands at $221,890,000.

Electra guides cash to fund operations into 2029 against pro forma cash of $417,575,000. Registrational enrollment completion is targeted for the second half of 2027, followed by topline data, BLA submission, and an FDA review cycle — sequencing neatly against that runway. Fierce Biotech reported that $220 million of the proceeds are earmarked for the sHLH registrational program through topline readout and BLA submission (Fierce Biotech, September 18, 2026), which embeds a material spend acceleration from the current run rate and explains why the 2029 endpoint is a genuine cash management boundary, not a conservative buffer. On the evidence available at filing, Electra will be raising again — either with SURPASS data in hand, or without them.

---

The manufacturing risk the deal marketing did not lead with

An FDA inspection of Electra's drug product CMO facility concluded in March 2026 with an Official Action Indicated classification. OAI means the agency found conditions warranting regulatory action at a facility in the supply chain that must support a future BLA. Electra's disclosed product liability coverage is $5,000,000, and the company relies on sole-source and limited-source suppliers by its own disclosure.

This risk has a recent and specific comparator. In June 2026, the FDA issued complete response letters to both Unicycive Therapeutics and Sobi on third-party manufacturing deficiencies — Unicycive's shares fell approximately half on that news (BioSpace, June 30, 2026). A CRL on CMC grounds does not invalidate a drug; it costs a re-inspection cycle and a re-submission. For a company whose cash runway guidance ends in the same window as its pivotal data, that cost is a financing event. The BIOSECURE Act — enacted December 2025 with a five-year grandfathering provision — adds a separate supply chain risk vector that warrants monitoring.

---

The dilution structure

Options outstanding under the 2022 Plan total 5,701,943 at a $4.92 weighted-average exercise price, plus 259,921 granted after June 30, 2026 at $7.03. The 2026 Plan reserves 13,446,281 shares, inclusive of 2,863,183 IPO option grants struck at the offer price. The ESPP reserves 611,682 shares. Combined, that pool totals approximately 19,961,806 shares — roughly 32% of the 62,766,955 post-IPO shares outstanding, before annual automatic increases. For a 46-employee company, the pool is sized for a commercial buildout that does not yet exist.

One additional capital structure item: a $9,675,000 deemed dividend to Series C preferred holders, recognized in the six months ended June 30, 2026. It does not affect the cash position, but it is an economics adjustment in favor of the last private round, booked months before the IPO.

---

The counter-case

The bull argument does not rest on the response rates — it rests on the regulatory posture. The FDA granted Breakthrough Therapy designation and the EMA granted PRIME for sHLH broadly, which means both agencies reviewed the same 12-patient dataset and the Expanded Access experience and were willing to designate against the wide indication. Regulators do not grant broad designations on data they consider mechanistically non-generalizable. If the agencies have already accepted the mechanistic bridge from mHLH to sHLH, the central risk in this brief is one Electra has partially retired in advance.

The market opportunity is real at this patient scale. Diagnosed US sHLH incidence was estimated at 12,600 in 2025, growing at an 11.5% compound annual rate since 2021 toward a projected 17,500 by 2028. Annual US T/NK malignancy incidence adds approximately 13,000 patients. US orphan drug exclusivity runs 7 years from approval. At roughly $523 million of implied asset value, that addressable population does not require aggressive penetration assumptions — which is precisely the condition under which a cautious valuation becomes a feature rather than a flag.

---

Falsification

The cautious read weakens if:

• SURPASS or COMPASS enrollment slips more than two quarters past the second-half-2027 target, pushing topline into the back half of the stated cash runway.
• Electra discloses any efficacy data in non-malignancy sHLH with response or survival rates materially below the 100% ORR seen in the 12 frontline mHLH patients — confirming the mechanistic extrapolation does not hold in infection- or autoimmune-triggered cases.
• The drug product CMO's OAI classification is not resolved to Voluntary Action Indicated or better before BLA submission.
• A follow-on equity raise arrives before SURPASS topline — the signal that the "into 2029" runway was built on a spend plan the board has since revised.

It strengthens if:

• Initial Phase 1 data in relapsed/refractory T/NK malignancies, expected in the second half of 2027, replicate anything close to the 88.0% complete response rate seen across the Phase 1b and Expanded Access cohort — converting this from a single-indication orphan story into a platform with a larger oncology shot.
• SURPASS trigger-mix disclosure shows a non-mHLH cohort with survival separation from COMPASS at an effect size that case-mix adjustment cannot erase.

Watch: Phase 1 T/NK malignancy readout, second half of 2027. Before that: any interim SURPASS enrollment disclosure revealing trigger-mix composition. And the CMO OAI resolution timeline, which carries no public deadline.